The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 1×
“Fibrils formed from synthetic IAPP and other amyloidogenic proteins rapidly show toxic properties to islet and other cells in vitro by an unknown mechanism [115, 116, 117]; insertion into the lipid bilayer and changes in cell membrane ion channel activity [118, 119] leading to apoptosis [12, 120], have been proposed.”
BackgroundIslet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.
Westermark, P., Engström, U., Johnson, K. H., Westermark, G. T., & Betsholtz, C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5036 · Cited by 807
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · cited 1×
“Islet amyloid deposits contain a variety of components that are common to all forms of amyloidosis; serum amyloid P component [41], apolipoprotein E (ApoE) and heparan sulphate proteoglycans [42, 43, 44] are present in addition to the proteinaceous fibrils; some of these molecules may play a role in the initiation or…”
BackgroundTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes.
Kahn, S. E., Andrikopoulos, S., & Verchere, C. B. (1999) · Diabetes · doi:10.2337/diabetes.48.2.241 · Cited by 488 · cited 2×
“Extensive islet amyloid deposition identified at post mortem has been correlated with reduced islet function and loss of islet beta cells in animal models [10] and with severe islet dysfunction associated with the need for insulin replacement therapy in humans [1, 11].”
BackgroundReceptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., et al. (2000) · Nature Medicine · doi:10.1038/76216 · Cited by 343
Opie, E. L. (1901) · Journal of Experimental Medicine · doi:10.1084/jem.5.5.527 · Cited by 305
Verchere, C. B., D'Alessio, D. A., Palmiter, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., & Kahn, S. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3492 · Cited by 278
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene
Botto, M., Hawkins, P. N., Bickerstaff, M. C. M., Herbert, J., Bygrave, A. E., Mcbride, A., Hutchinson, W. L., Tennent, G. A., Walportz, M. J., & Pepys, M. B. (1997) · Nature Medicine · doi:10.1038/nm0897-855 · Cited by 266 · cited 3×
“A proposal has been made that all amyloid deposits are being degraded continuously [110], possibly by removal by macrophages, and that accumulation of deposits could result from a deficiency in the factors responsible for degradation and/or turnover [111].”
BackgroundKahn, S. E., & Halban, P. A. (1997) · Diabetes · doi:10.2337/diabetes.46.11.1725 · Cited by 221
Kahn, S. E., & Halban, P. A. (1997) · Diabetes · doi:10.2337/diab.46.11.1725 · Cited by 221
Hartter, E., Svoboda, T., Ludvik, B., Schuller, M., Lell, B., Kuenburg, E., Brunnbauer, M., Woloszczuk, W., & Prager, R. (1991) · Diabetologia · doi:10.1007/bf00404025 · Cited by 191 · cited 1×
“In addition, insulin and IAPP are co-ordinately regulated in terms of gene expression [85] and circulating concentrations in glucose intolerance and diabetes in man [16, 84, 86, 87]; disassociation of the two beta-cell products does howIslet amyloid: a complication of islet dysfunction or an aetiological factor in Typ…”
BackgroundIncreased Insulin Secretion and Glucose Tolerance in Mice Lacking Islet Amyloid Polypeptide (Amylin)
Gebre-Medhin, S., Mulder, H., Pekny, M., Westermark, G., Törnell, J., Westermark, P., Sundler, F., Ahrén, B., & Betsholtz, C. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9308 · Cited by 157 · cited 1×
“logical roles have been attributed to IAPP since its identification in 1987 [34, 35], it remains a peptide without a clearly identified function in vivo [36]; moderately improved glucose intolerance was detected in the IAPP knock-out mouse [37, 38] and Type 1 diabetic subjects do not have pathophysiological features w…”
BackgroundHöppener, J. W. M., Oosterwijk, C., Nieuwenhuis, M. G., Posthuma, G., Thijssen, J. H. H., Vroom, T. M., Ahrén, B., & Lips, C. J. M. (1999) · Diabetologia · doi:10.1007/s001250051175 · Cited by 153
Sanke, T., Hanabusa, T., Nakano, Y., Oki, C., Okai, K., Nishimura, S., Kondo, M., & Nanjo, K. (1991) · Diabetologia · doi:10.1007/bf00500385 · Cited by 149
Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide.
Soeller, W. C., Janson, J., Hart, S. E., Parker, J. C., Carty, M. D., Stevenson, R. W., Kreutter, D. K., & Butler, P. C. (1998) · Diabetes · doi:10.2337/diabetes.47.5.743 · Cited by 140 · cited 2×
“Amyloid deposition in obese or fat-fed hIAPP TM is more frequent in males [96, 97], is reversed by oestrogen treatment in obese male animals [98] and is increased in hIAPP females by oophorectomy despite no change in circulating concentrations of IAPP [99].”
BackgroundIslet amyloid polypeptide in diabetic and non-diabetic Pima Indians
Clark, A., Saad, M. F., Nezzer, T., Uren, C., Knowler, W. C., Bennett, P. H., & Turner, R. C. (1990) · Diabetologia · doi:10.1007/bf00403322 · Cited by 119
Self-citationEnoki, S., Mitsukawa, T., Takemura, J., Nakazato, M., Aburaya, J., Toshimori, H., & Matsukara, S. (1992) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(92)90074-2 · Cited by 118 · cited 3×
“Monomeric nonglycated hIAPP does not bind to this receptor but fibrillar IAPP (and amyloid fibrils composed of other proteins) have been shown to interact [84].”
BackgroundO'Brien, T. D., Westermark, P., & Johnson, K. H. (1991) · Diabetes · doi:10.2337/diab.40.12.1701 · Cited by 108
Kahn, S. E., Verchere, C. B., Andrikopoulos, S., Asberry, P. J., Leonetti, D. L., Wahl, P. W., Boyko, E. J., Schwartz, R. S., Newell-Morris, L., & Fujimoto, W. Y. (1998) · Diabetes · doi:10.2337/diabetes.47.4.640 · Cited by 74
Cited by
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044
“Second, the role of aggregated IAPP in the development of the -cell lesion in type 2 diabetes has not yet become generally accepted (60, 401).”
BackgroundDiabetes Mellitus and the β Cell: The Last Ten Years
Ashcroft, F. M., & Rorsman, P. (2012) · Cell · doi:10.1016/j.cell.2012.02.010 · Cited by 902
Arsenic-induced oxidative stress and its reversibility
Flora, S. J. S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.008 · Cited by 824
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis
Haataja, L., Gurlo, T., Huang, C. J., & Butler, P. C. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0037 · Cited by 612
Metadata
- Authors
- Clark, A., & Nilsson, M. R.
- Venue
- Diabetologia
- Published
- 2004-02-01
- Volume
- 47
- Issue
- 2
- Pages
- 157-169
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2095481422
- Cited by
- 186
- References
- 21
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.